| [1] |
王红, 曹梦迪, 刘成成, 等. 中国人群结直肠癌疾病负担:近年是否有变?[J]. 中华流行病学杂志, 2020, 41(10): 1633-1642.
|
| [2] |
中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-直肠癌部分 [J/OL]. 中华结直肠疾病电子杂志, 2022, 11(2): 89-103.
|
| [3] |
van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study[J]. Lancet, 2018, 391(10139): 2537-2545.
|
| [4] |
Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer [J]. J Clin Oncol, 2012, 30(15): 1770-1776.
|
| [5] |
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation [J]. Nature, 2008, 454(7203): 436-444.
|
| [6] |
Mishra A, Liu S, Sams G, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation [J]. Cancer Cell, 2012, 22(5): 645-655.
|
| [7] |
Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance [J]. Immunity, 2013, 39(1): 74-88.
|
| [8] |
Ko EC, Formenti SC. Radiotherapy and checkpoint inhibitors: a winning new combination? [J]. Ther Adv Med Oncol, 2018, 10: 1758835918768240.
|
| [9] |
Teng F, Mu D, Meng X, et al. Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer [J]. Am J Cancer Res, 2015, 5(6): 2064.
|
| [10] |
Teng F, Meng X, Kong L, et al. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer [J]. Transl Res, 2015, 166(6): 721-732.
|
| [11] |
Heo J, Chun M, Noh OK, et al. Sustaining blood lymphocyte count during preoperative chemoradiotherapy as a predictive marker for pathologic complete response in locally advanced rectal cancer [J]. Cancer Res Treat, 2016, 48(1): 232.
|
| [12] |
Tada N, Kawai K, Tsuno NH, et al. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets [J]. World J Surg Oncol, 2015, 13(1): 30.
|
| [13] |
Heo J, Oh YT, Noh OK, et al. Nodal tumor response according to the count of peripheral blood lymphocyte subpopulations during preoperative chemoradiotherapy in locally advanced rectal cancer [J]. Radiat Oncol J, 2016, 34(4): 305-312.
|
| [14] |
Lan HR, Du WL, Liu Y, et al. Role of immune regulatory cells in breast cancer: Foe or friend?[J]. Int Immunopharmacol, 2021, 96(4): 107627.
|
| [15] |
Augier S, Ciucci T, Luci C, et al. Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance [J]. J Immunol, 2010, 185(12): 7165-7173.
|
| [16] |
Ishikawa D, Nishi M, Takasu C, et al. The role of neutrophil-to-lymphocyte ratio on the effect of CRT for patients with rectal cancer [J]. In Vivo, 2020, 34(2): 863-868.
|
| [17] |
Wang Y, Chen L, Zhang B, et al. Pretreatment inflammatory- nutritional biomarkers predict responses to neoadjuvant chemoradiotherapy and survival in locally advanced rectal cancer [J]. Front Oncol, 2021, 11: 479.
|
| [18] |
Kim TG, Park W, Kim H, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy [J]. Tumori, 2018, 105(5): 434-440.
|
| [19] |
Li A, He K, Guo D, et al. Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer [J]. Future Oncol, 2019, 15(28): 3233-3242.
|
| [20] |
Lee JH, Song C, Kang SB, et al. Predicting pathological complete regression with haematological markers during neoadjuvant chemoradiotherapy for locally advanced rectal cancer [J]. Anticancer Res, 2018, 38(12): 6905-6910.
|
| [21] |
Yang J, Xu H, Guo X, et al. Pretreatment inflammatory indexes as prognostic predictors for survival in colorectal cancer patients receiving neoadjuvant chemoradiotherapy [J]. Sci Rep, 2018, 8(1): 3044.
|
| [22] |
Abe S, Kawai K, Nozawa H, et al. LMR predicts outcome in patients after preoperative chemoradiotherapy for stage II-III rectal cancer [J]. J Surg Res, 2018, 222: 122-131.
|
| [23] |
Deng YX, Lin JZ, Peng JH, et al. Lymphocyte-to-monocyte ratio before chemoradiotherapy represents a prognostic predictor for locally advanced rectal cancer [J]. Onco Targets Ther, 2017, 10: 5575-5583.
|
| [24] |
Chen L, Kong X, Wang Z, et al. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy [J]. J Cell Mol Med, 2020, 24(5): 2993-3021.
|
| [25] |
Murthy P, Zenati MS, Abbas A, et al. Prognostic value of the systemic immune-inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer [J]. Ann Surg Oncol, 2019, 27(3): 898-906.
|
| [26] |
Jomrich G, Paireder M, Kristo I, et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma [J]. Ann Surg, 2021, 273(3): 532-541.
|
| [27] |
Jiang C, Lu Y, Zhang S, et al. Systemic immune-inflammation index is superior to neutrophil to lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy [J]. Biomed Res Int, 2020, 2020(4): 1-10.
|
| [28] |
Sun Y, Huang Z, Chi P. An inflammation index-based prediction of treatment response to neoadjuvant chemoradiotherapy for rectal mucinous adenocarcinoma [J]. Int J Clin Oncol, 2020, 25(486-492): 1-9.
|
| [29] |
Eraslan E, Adas YG, Yildiz F, et al. Systemic immune-inflammation index (SII) predicts pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. J Coll Physicians Surg Pak, 2021, 30(4): 399-404.
|
| [30] |
Haskins IN, Baginsky M, Amdur RL, et al. Preoperative hypoalbuminemia is associated with worse outcomes in colon cancer patients [J]. Clin Nutr, 2017, 36(5): 1333-1338.
|
| [31] |
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature [J]. Nutr J, 2010, 9(1): 1-16.
|
| [32] |
Chen S, Nie RC, Ouyang LY, et al. Body mass index (BMI) may be a prognostic factor for gastric cancer with peritoneal dissemination [J]. World J Surg Oncol, 2017, 15(1): 52.
|
| [33] |
Ejaz A, Spolverato G, Kim Y, et al. Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer[J]. J Surg Res, 2015, 195(1): 74-82.
|
| [34] |
Uratani R, Toiyama Y, Shimura T, et al. Preoperative lower body mass index correlates with poorer prognosis in patients undergoing curative laparoscopic surgery for colorectal cancer [J]. Anticancer Res, 2015, 35(10): 5639-5648.
|
| [35] |
Chiang JM, Chang CJ, Jiang SF, et al. Pre-operative serum albumin level substantially predicts post-operative morbidity and mortality among patients with colorectal cancer who undergo elective colectomy [J]. Eur J Cancer Care, 2017, 26(2):10.1111/ecc.12403.
|
| [36] |
Yamana I, Takeno S, Shimaoka H, et al. Geriatric nutritional risk index as a prognostic factor in patients with esophageal squamous cell carcinoma -retrospective cohort study [J]. Int J Surg, 2018, 56: 44-48.
|
| [37] |
Kubo N, Sakurai K, Tamura T, et al. The impact of geriatric nutritional risk index on surgical outcomes after esophagectomy in patients with esophageal cancer [J]. Esophagus, 2019, 16(2): 147-154.
|
| [38] |
Sasaki M, Miyoshi N, Fujino S, et al. The geriatric nutritional risk index predicts postoperative complications and prognosis in elderly patients with colorectal cancer after curative surgery [J]. Sci Rep, 2020, 10(1): 10744.
|
| [39] |
Haruaki H, Tomohito S, Hiroshi M, et al. Utility of geriatric nutritional risk index in patients with lung cancer undergoing surgery [J]. Eur J Cardiothorac Surg, 2020, 58(4): 775-782.
|
| [40] |
Ide S, Okugawa Y, Omura Y, et al. Geriatric nutritional risk index predicts cancer prognosis in patients with local advanced rectal cancer undergoing chemoradiotherapy followed by curative surgery [J]. World J Surg Oncol, 2021, 19(1):34.
|
| [41] |
Lee-Rueckert M, Escola-Gil JC, Kovanen PT. HDL functionality in reverse cholesterol transport—Challenges in translating data emerging from mouse models to human disease [J]. Biochim Biophys Acta, 2016, 1861(7): 566-583.
|
| [42] |
Zamanian-Daryoush M, Lindner D, Tallant TC, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects [J]. J Biol Chem, 2013, 288(29): 21237-21252.
|
| [43] |
Ben Hassen C, Gutierrez-Pajares JL, Guimaraes C, et al. Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells [J]. Breast Cancer Res, 2020, 22(1): 38.
|
| [44] |
Guo SP, Chen C, Zeng ZF, et al. Serum apolipoprotein A-I predicts response of rectal cancer to neoadjuvant chemoradiotherapy [J]. Cancer Manag Res, 2021, 13: 2623-2631.
|
| [45] |
Kakuda H, Matoba M, Nakatoh H, et al. Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia [J]. J Clin Lipidol, 2015, 9(5): 709-715.
|
| [46] |
Pang J, Chan DC, Hamilton SJ, et al. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus [J]. Arterioscler Thromb Vasc Biol, 2014, 34(2): 427-432.
|
| [47] |
Karagkounis G, DeVecchio J, Ferrandon S, et al. Simvastatin enhances radiation sensitivity of colorectal cancer cells [J]. Surg Endosc, 2018, 32(3): 1533-1539.
|
| [48] |
Moureau-Zabotto L, Farnault B, de Chaisemartin C, et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer [J]. Int J Radiat Oncol Biol Phys, 2011, 80(2): 483-491.
|
| [49] |
Tan Y, Fu D, Li D, et al. Predictors and risk factors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer: a population-based analysis [J]. Front Oncol, 2019, 9: 497.
|
| [50] |
Zheng Z, Wang X, Huang Y, et al. Predictive value of changes in the level of carbohydrate antigen 19-9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy [J]. Colorectal Dis, 2020, 22(12): 2068-2077.
|
| [51] |
Song J, Huang X, Chen Z, et al. Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0-I after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. Cancer Manag Res, 2018, 10: 3101-3108.
|
| [52] |
Deng HY, Zhu XQ, Ding YY, et al. Multislice spiral CT images combined with CEA and lymphocyte-to-neutrophil ratio predict recurrence and post-operative metastasis of rectal cancer [J]. Mol Cell Probes, 2020, 50: 101502.
|
| [53] |
Lu S, Liu Z, Wang B, et al. High CFP score indicates poor prognosis and chemoradiotherapy response in LARC patients [J]. Cancer Cell Int, 2021, 21(1): 205.
|
| [54] |
Yoo GS, Park HC, Yu JI, et al. Carcinoembryonic antigen improves the performance of magnetic resonance imaging in the prediction of pathologic response after neoadjuvant chemoradiation for patients with rectal cancer [J]. Cancer Res Treat, 2020, 52(2): 446-454.
|
| [55] |
Liu Y, Zhang FJ, Zhao XX, et al. Development of a joint prediction model based on both the radiomics and clinical factors for predicting the tumor response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer [J]. Cancer Manag Res, 2021, 13: 3235-3246.
|
| [56] |
Cheng Y, Luo Y, Hu Y, et al. Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer [J]. Abdom Radiol, 2021, 46(11): 5072-5085.
|